Drugs for Multiple Endocrine Neoplasia, Type I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 50)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dexlansoprazole |
Approved, Investigational |
Phase 4 |
|
138530-94-6, 103577-45-3 |
9578005 |
Synonyms:
138530-94-6
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
CHEMBL1201863
CID9578005
D08903
dexlansoprazole
Dexlansoprazole
Dexlansoprazole (INN/USAN)
|
Kapidex
KS-1075
MolPort-002-885-834
T 168390
TAK 390
UNII-UYE4T5I70X
ZINC00599734
|
|
2 |
|
Lansoprazole |
Approved, Investigational |
Phase 4 |
|
103577-45-3 |
3883 |
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
A 65006
A-65006
AB00052388
Abbot brand OF lansoprazole
Abbot Brand of Lansoprazole
ABT-006
AC1L1GX8
AG 1749
AG-1749
Agopton
Almirall brand OF lansoprazole
Almirall Brand of Lansoprazole
Amarin
Aprazol
Bamalite
BIDD:GT0006
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
Compraz
CPD000058469
D00355
Dakar
DB00448
DivK1c_000920
EU-0100709
FT-0082011
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
Hoechst brand OF lansoprazole
Hoechst Brand of Lansoprazole
Hormona brand OF lansoprazole
Hormona Brand of Lansoprazole
HSDB 7204
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
L 8533
L8533_SIGMA
Lancid
Lanfast
Lanproton
Lansol
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
lansoprazole
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole [Usan:Ban:Inn]
Lansoprazole [USAN:BAN:INN]
Lansoprazole abbot brand
Lansoprazole almirall brand
Lansoprazole hoechst brand
Lansoprazole hormona brand
Lansoprazole lederle brand
Lansoprazole promeco brand
Lansoprazole salvar brand
Lansoprazole sodium
lansoprazole sulphone
Lansoprazole takeda brand
Lansoprazole tap brand
Lansoprazole tecnobio brand
Lansoprazole vinas brand
Lansoprazole wyeth brand
|
Lansoprazoles
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
Lanston
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
lanzoprazole
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle brand OF lansoprazole
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac0_000709
Lopac-L-8533
LS-33080
Mesactol
MLS000069705
MLS-0003247.0001
MLS000759405
MLS001074170
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
Prevacid
Prevacid (TN)
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid Solutab
Prevacid SoluTab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
PrevOnco
Prevpac
Prezal
Pro ulco
Pro Ulco
Promeco
Promeco brand OF lansoprazole
Promeco Brand of Lansoprazole
Promp
Prosogan
S1354_Selleck
Salvar brand OF lansoprazole
Salvar Brand of Lansoprazole
SAM001246544
SMR000058469
Sodium, lansoprazole
SPBio_000488
SPBio_002992
Spectrum_001580
SPECTRUM1503926
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
STK621169
Suprecid
TAK 390MR
TAK390MR
TAK-390MR
Takeda brand OF lansoprazole
Takeda Brand of Lansoprazole
Takepron
TAP brand OF lansoprazole
TAP Brand of Lansoprazole
Tecnobio brand OF lansoprazole
Tecnobio Brand of Lansoprazole
TL8000155
Ulpax
UNII-0K5C5T2QPG
Vinas brand OF lansoprazole
Vinas Brand of Lansoprazole
Wyeth brand OF lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
|
|
3 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
4 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
5 |
|
Antacids |
|
Phase 4 |
|
|
|
6 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
7 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
51110-01-1, 38916-34-6 |
53481605 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
Growth hormone-inhibiting hormone (ghih)
Somatostatin
Somatostatina
Somatostatine
|
Somatostatinum
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
8 |
|
Hormones |
|
Phase 3 |
|
|
|
9 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
10 |
|
Barley |
Approved |
Phase 2 |
|
|
|
11 |
|
Octreotide |
Approved, Investigational |
Phase 2 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
Compound 201 995
Compound 201995
Compound 201-995
D00442
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DRG-0115
HMS2090C09
HS-2020
L000453
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
|
Longastatin
LS-177735
LS-187135
NCGC00181796-01
nchembio.184-comp3
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide acetate salt
Octreotide Acetate Salt
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
Sandostatin
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SM 201-995
SMS 201-995
SMS-201-995
UNII-RWM8CCW8GP
zacycloicosane-4-carboxamide acetate
|
|
12 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
6442177 70789204 |
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
Everolimus
|
évérolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
13 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
|
Synonyms:
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
E7080
|
|
|
14 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-rapamycin
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic ay 22989
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
Rapamysin
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
Sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
Sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
15 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 406563 |
Synonyms:
284461-73-0
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafénib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
16 |
|
Pertuzumab |
Approved |
Phase 2 |
|
380610-27-5, 145040-37-5 |
2540 |
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
Omnitarg
|
Perjeta
pertuzumab
Pertuzumab
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
Pertuzumab (USAN/INN)
rhuMAb 2C4
rhuMAb-2C4
|
|
17 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
18 |
|
Nutrients |
|
Phase 2 |
|
|
|
19 |
|
Mitogens |
|
Phase 2 |
|
|
|
20 |
|
Endothelial Growth Factors |
|
Phase 2 |
|
|
|
21 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
22 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
23 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
24 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
26 |
|
Erlotinib Hydrochloride |
|
Phase 2 |
|
183319-69-9 |
176871 |
Synonyms:
|
27 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
28 |
|
gamma-Globulins |
|
Phase 1 |
|
|
|
29 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
30 |
|
Antibodies |
|
Phase 1 |
|
|
|
31 |
|
Rho(D) Immune Globulin |
|
Phase 1 |
|
|
|
32 |
|
Morphine |
Approved, Investigational |
|
|
57-27-2 |
5288826 |
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
HSDB 2134
|
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
Morfina
Morfina [Italian]
Morfina dosa
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Substitol
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
33 |
|
Histamine |
Approved, Investigational |
|
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
34 |
|
Vancomycin |
Approved |
|
|
1404-90-6 |
441141 14969 |
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-b-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-b-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
1404-90-6
1404-93-9 (hydrochloride)
64685-75-2 (sulfate)
Abbott brand OF vancomycin hydrochloride
AB-vancomycin
AC1L24VU
AC1L9AMI
AC1Q29OH
Azupharma brand OF vancomycin hydrochloride
BIDD:GT0353
C06689
C66H75Cl2N9O24
Cell pharm brand OF vancomycin hydrochloride
CHEBI:28001
CHEMBL262777
Chiesi brand OF vancomycin hydrochloride
CID14969
CID441141
CID5311496
CID6426898
CID6917992
Combino brand OF vancomycin hydrochloride
Curasan brand OF vancomycin hydrochloride
D00212
Dakota brand OF vancomycin hydrochloride
DB00512
Diatracin
Dista brand OF vancomycin hydrochloride
EINECS 215-772-6
Eli lilly brand OF vancomycin hydrochloride
Hexal brand OF vancomycin hydrochloride
HSDB 3262
Hydrochloride, vancomycin
Lilly brand OF vancomycin hydrochloride
LMPK14000004
Lopac0_001267
LS-161387
|
MIP brand OF vancomycin hydrochloride
MolPort-001-794-649
NCGC00162383-02
nchembio.350-comp1
Norman brand OF vancomycin hydrochloride
Prestwick0_000497
Prestwick1_000497
Prestwick2_000497
Ratiopharm brand OF vancomycin hydrochloride
SPBio_002314
Sulfate, vancomycin
UNII-6Q205EH1VU
VAN
Vanco azupharma
Vanco-cell
Vancocin
Vancocin (TN)
Vancocin HCL
Vancocine
Vancoled
Vancomicin
Vancomicina
Vancomicina [INN-Spanish]
Vancomicina abbott
Vancomicina chiesi
Vancomicina combino phar
Vancomicina norman
Vancomycin
VANCOMYCIN
Vancomycin (USP)
Vancomycin [USAN:INN:BAN]
Vancomycin HCL
Vancomycin hexal
Vancomycin hydrochloride
Vancomycin lilly
Vancomycin phosphate (1:2)
Vancomycin phosphate (1:2), decahydrate
Vancomycin sulfate
Vancomycine
Vancomycine [INN-French]
Vancomycine dakota
Vancomycin-ratiopharm
Vancomycinum
Vancomycinum [INN-Latin]
Vancor
Vanco-saar
|
|
35 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
36 |
|
Salmon calcitonin |
Approved, Investigational |
|
|
47931-85-1 |
16129616 |
Synonyms:
135506-95-5
47931-85-1
Astronin
Biocalcin
Bionocalcin
C028815
C06865
C145H239N43O48S2
Cadens
Calciben
Calcihexal
Calcimar
Calcimar (TN)
Calcimonta
Calcinil
Calcioton
Calcitonin (Salmon Synthetic)
Calcitonin (salmon)
Calcitonin [USAN:INN:BAN:JAN]
Calcitonin salmon
Calcitonin salmon (synthesis)
Calcitonin salmon (synthesis) (JAN)
Calcitonin salmon (USAN/INN)
Calcitonin salmon recombinant
Calcitonin vom lachs
Calcitonin, salmar
Calcitonin, salmon
CALCITONIN, SALMON
Calcitonin, salmon, for bioassay
Calcitonin,salmon
Calcitonina
Calcitonina salmón sintética
Calcitonine de saumon
Calcitonin-salmon
Calcitoran
Calco
Calogen
Calsynar
Calsynar Lyo L
Caltine
Casalm
Catonin
Cibacalcin
Cibacalcine
Citonina
D00249
|
EINECS 256-342-8
Eptacalcin
Forcaltonin
Fortical
Fortical (TN)
Ipocalcin
Isi-calcin
Kalsimin
Karil
LS-48624
Miacalcic
Miacalcin
Miacalcin (TN)
Miracalcic
Oseototal
Osseocalcina
Osteobion
Osteovis
Ostosalm
Ostostabil
Porostenina
Prontocalcin
Quosten
recombinant salmon calcitonin
Recombinant salmon calcitonin
Riostin
Rulicalcin
Salcat
Salcatonin
Salcatyn
Salmocalcin
Salmofar
Salmon calcitonin
salmon calcitonin (1-32)
Salmon calcitonin I
Salmon calcitonin-(I-32)
Sical
Stalcin
Staporos
Steocin
synthetic salmon calcitonin
Thyrocalcitonin (salmon)
Tonocalcin
TZ-CT
Ucecal
UNII-7SFC6U2VI5
|
|
37 |
|
Pancrelipase |
Approved, Investigational |
|
|
53608-75-6 |
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
38 |
|
Parathyroid hormone |
Approved, Investigational |
|
|
9002-64-6 |
|
Synonyms:
Parathormone
Parathormone (human recombinant)
Parathyrin
Parathyroid hormone
Parathyroid hormone (1-84) human recombinant
Parathyroid hormone (rDNA)
|
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
39 |
|
Formaldehyde |
Approved, Vet_approved |
|
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
Formalin
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
|
Formol
Hyperband
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
40 |
|
Phenylalanine |
Approved, Investigational, Nutraceutical |
Early Phase 1 |
|
63-91-2 |
6140 |
Synonyms:
(-)-beta-Phenylalanine
(2S)-2-amino-3-phenylpropanoic acid
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-Amino-3-phenylpropionic acid
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-alpha-Amino-beta-phenylpropionic acid
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
10549-09-4
1f2p
1F9436B3-8B0D-4AC6-A004-4249B0BDA436
1usi
3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
303-47-9 OCHRATOXINA
32526-17-3
35849-41-3
3617-44-5
3-Phenylalanine
3-phenyl-l-alanine
3-phenyl-L-alanine
3-Phenyl-L-alanine
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
5297-02-9
63-91-2
673-06-3 D-PHENYL)
67675-33-6
78019_FLUKA
78019_SIGMA
801204-11-5
AB1003608
AC1L1LVU
AC1L1XF0
alpha-Aminohydrocinnamate
alpha-Aminohydrocinnamic acid
AmbotzHAA1121
Antibiotic FN 1636
beta-Phenylalanine
beta-Phenyl-alpha-alanine
beta-phenyl-l-alanine
beta-Phenyl-L-alanine
bmse000045
b-Phenyl-L-alanine
C00079
CB 3208
CCRIS 4254
CHEBI:17295
CHEMBL301523
CID37278
CID6140
D00021
DB00120
DB02556
|
EINECS 200-568-1
endophenyl
Endorphenyl
F
FEMA No. 3585
fenilalanina
Fenilalanina
Fenilalanina [Spanish]
H-Phe-OH
HSDB 1825
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine
L-Antibiotic FN 1636
L-Isomer phenylalanine
L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME
L-phenylalanine
L-Phenylalanine
L-Phenylalanine (JP15)
L-Phenylalanine,
L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl- (9CI)
L-PHENYLALININE
LS-1515
LS-15879
MolPort-001-757-101
NCGC00013103
NCGC00095047-01
NCGC00095047-02
NCGC00095047-03
NCGC00095047-04
nchembio.185-comp8
nchembio.186-comp89
nchembio.255-comp2
nchembio816-comp8
NCI9959
NCIStruc1_000204
NCIStruc2_000248
N-Formyl-L-p-sarcolysin
N-Formyl-L-sarcolysin
N-Formylmelphalan
NSC 37024
NSC 79477
NSC37024
NSC-9959
P0134
P2126_SIAL
P5482_SIGMA
P8740_SIAL
P8740_SIGMA
phe
Phe
Phenylalamine
phenylalanine
Phenylalanine
Phenyl-alanine
PHENYLALANINE
Phenylalanine (USP/INN)
Phenylalanine (VAN)
Phenylalanine [USAN:INN:JAN]
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Phenylalaninum [Latin]
Tetrahydrofolate
THF
UNII-47E5O17Y3R
W358509_ALDRICH
β-phenyl-L-alanine
Î’-phenyl-L-alanine
|
|
41 |
|
Calcitonin gene-related peptide |
Investigational |
|
|
83652-28-2 |
|
Synonyms:
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
42 |
|
Radiopharmaceuticals |
|
Early Phase 1 |
|
|
|
43 |
|
Edotreotide |
|
Early Phase 1 |
|
|
|
44 |
|
Dihydroxyphenylalanine |
|
|
|
|
|
45 |
|
Histamine Phosphate |
|
|
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
46 |
|
Calcium, Dietary |
|
|
|
|
|
47 |
|
calcitonin |
|
|
|
|
|
48 |
|
Katacalcin |
|
|
|
|
|
49 |
|
pancreatin |
|
|
|
|
|
50 |
|
Calcium |
Nutraceutical |
|
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show all 35)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors |
Completed |
NCT00204373 |
Phase 4 |
Lansoprazole (Prevacid) |
2 |
Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study |
Not yet recruiting |
NCT02705651 |
Phase 3 |
Somatostatin-Analog |
3 |
A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention |
Unknown status |
NCT02869399 |
Phase 2 |
|
4 |
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors |
Completed |
NCT02101918 |
Phase 2 |
|
5 |
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma |
Completed |
NCT00454363 |
Phase 2 |
Pazopanib Hydrochloride |
6 |
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma |
Completed |
NCT00514046 |
Phase 1, Phase 2 |
Vandetanib |
7 |
A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMAâ„¢ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
Completed |
NCT00358956 |
Phase 2 |
ZD6474 (vandetanib) |
8 |
Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study |
Completed |
NCT00990535 |
Phase 2 |
Octreotide-LAR |
9 |
A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors |
Recruiting |
NCT03950609 |
Phase 2 |
Everolimus;Lenvatinib |
10 |
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma |
Active, not recruiting |
NCT00390325 |
Phase 2 |
Sorafenib Tosylate |
11 |
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors |
Terminated |
NCT00947167 |
Phase 2 |
pertuzumab;erlotinib |
12 |
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial |
Completed |
NCT00001550 |
Phase 1 |
IVIg |
13 |
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors |
Withdrawn |
NCT02831179 |
Phase 1 |
Capecitabine;Temozolomide;Veliparib |
14 |
Type 1 Multiple Endocrine Neoplasia : a Cohort Study of the Endocrine Tumor Study Group (GTE) |
Unknown status |
NCT03262129 |
|
|
15 |
A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer |
Unknown status |
NCT00672269 |
|
|
16 |
An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC |
Completed |
NCT03001349 |
Early Phase 1 |
Gallium Ga 68-Edotreotide |
17 |
A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers |
Completed |
NCT01794676 |
|
|
18 |
Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients |
Completed |
NCT01424878 |
|
|
19 |
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes |
Completed |
NCT00501449 |
|
|
20 |
Studies of Hyperparathyroidism and Related Disorders |
Completed |
NCT00001277 |
|
68Ga-Dotatate;18F-DOPA |
21 |
Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS) |
Completed |
NCT00824122 |
|
|
22 |
Reversal of Atrial Substrate to Prevent Atrial Fibrillation - A Pilot Study |
Completed |
NCT03186976 |
|
|
23 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
24 |
Familial Investigations of Childhood Cancer Predisposition |
Recruiting |
NCT03050268 |
|
|
25 |
Study and Follow-up of Multiple Endocrine Neoplasia Type 1 |
Recruiting |
NCT03348501 |
|
|
26 |
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients |
Recruiting |
NCT03048266 |
|
|
27 |
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 |
Recruiting |
NCT03048279 |
|
|
28 |
Family Studies in Metabolic Diseases and Mineral Metabolism |
Recruiting |
NCT00001345 |
|
|
29 |
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) |
Recruiting |
NCT03053999 |
|
|
30 |
Establishment of a Parathyroid Tissue Bank |
Recruiting |
NCT03051126 |
|
|
31 |
Reversal of Atrial Substrate to Prevent Atrial Fibrillation |
Recruiting |
NCT03682991 |
|
|
32 |
Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) |
Active, not recruiting |
NCT03043508 |
|
|
33 |
Study and Monitoring of Multiple Endocrine Neoplasia Type 1 |
Not yet recruiting |
NCT03966612 |
|
|
34 |
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) |
Not yet recruiting |
NCT04028479 |
|
Systemic Treatment (T) |
35 |
Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients |
Terminated |
NCT03044600 |
|
|
|